IDDI Workstreams & Task Forces

Actively finding practical solutions to the key challenges facing Pulmonary Hypertension (PH) physicians, academics, industry, and regulators; raising awareness of Pulmonary Vascular Disease (PVD); and addressing key challenges in its causes, effects, and treatment. 

Innovative Drug Development Initiative (IDDI) Workstreams 

The IDDI is a global, collaborative forum where representatives from academia, the pharmaceutical industry (established and emerging biotechnology), and drug regulators openly discuss questions surrounding the future of trials involving novel drugs. See our IDDI Special collection on Clinical Trial Design: Past, Present, and Future.

We believe in the power of early and ongoing dialogue with all stakeholders in the drug development process, including the crucial perspective of patients and their advocates. The IDDI aspires to explore novel approaches for combating and treating PVD and PH, focusing strongly on patient needs. There are eight IDDI Workstreams, each assigned to address various challenges PH patients face.  

Task Forces 

Our Disease and Specialty Task Forces focus on research into specific areas of PVD. They support us in understanding and implementing our vision and mission. Our Regional Task Forces focus on the key challenges facing patients, clinicians and researchers in their country or region. Several Regional Task Forces were impacted by the Covid pandemic and are currently inactive, but some are in the process of re-forming, such as the South East Asia Task Force and China Task Force. 

Find out more about each IDDI Workstream or Task Force below. PVRI members who are interested in contributing are encouraged to join. 

Reset filters

Leaders

Vijay Balasubramanian, Valley Advanced Lung Disease Institute
Yan Liu, United Therapeutics Corporation

Supported by

Alex Kantorovich, United Therapeutics Corporation
Sandeep Sahay, Houston Methodist
Innovative Drug Development Initiative (IDDI) Workstreams

Leaders

Franz Rischard, University of Arizona College of Medicine
David Systrom, Brigham and Women's Hospital
Aaron Waxman, Brigham and Women's Hospital
Disease and Specialty Task Forces

Leaders

Aastha Mishra, Institute of genomics and integrative biology (CSIR), India
Silvia Ulrich, University Hospital of Zurich, Switzerland
Disease and Specialty Task Forces

Leaders

David Kiely, University of Sheffield
David Levin, Mayo Clinic College of Medicine
Andy Swift, University of Sheffield
Rebecca Vanderpool, University of Arizona College of Medicine
Disease and Specialty Task Forces

Leaders

Prashant Bobhate, Kokilaben Dhirubai Ambani Hospital
Regional Task Forces

Leaders

Navneet Kaur Dhillon, University of Kansas Medical Centre, USA
Ghazwan Butrous, University of Kent, UK
Rudolf Oliveira, Federal University of São Paulo, Brazil
Suellen Darc Oliveira, University of Illinois at Chicago, USA
Vinicio de Jesus Perez, Stanford University, USA
Peter Nyasulu, Stellenbosch University, South Africa
Sharilyn Almadovar, Texas Tech University Health Sciences Centre, USA
Disease and Specialty Task Forces

Leaders

Vinicio de Jesus Perez, Stanford University
Gabriel Diaz, Universidad Nacional de Colombia
Gustavo Heresi, Cleveland Clinic
Mauricio Orozco-Levi, Universidad Nacional de Colombia
Tomas Pulido, Instituto Nacional de Cardiología
Rogerio Souza, University of Sao Paulo Medical School
Regional Task Forces